Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Tumour Site

Melanoma

Presenters

Viola Franke

Citation

Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255

Authors

V. Franke1, E.H.A. Stahlie2, B. van der Hiel3, B.A. van de Wiel4, M.W.J.M. Wouters5, W. Van Houdt1, A.C.J. van Akkooi6

Author affiliations

  • 1 Surgical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066CX - Amsterdam/NL
  • 2 Surgical Oncology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 3 Nuclear Medicine, Antoni van Leeuwenhoek - Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 4 Department Of Pathology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 5 Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 6 Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066CX - Amsterdam/NL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5666

Background

Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1 (HSV-1), which can be administered intralesionally in patients with stage IIIB/C-IVM1a unresectable melanoma.

Methods

5 patients with recurrent disease recommenced treatment with T-VEC monotherapy at the Netherlands Cancer Institute after a prior achieved CR. We collected data on response, adverse events (AE) and baseline characteristics. For response evaluation, we used clinical evaluation with photography, 3-monthly PET-CT’s and histological biopsies.

Results

All 5 patients had in-transit metastases on the lower limb. Median age at baseline was 72.1 years with a median follow-up time of 24.5 months. Histologically proven CR (pCR) was achieved after a median of 8 T-VEC courses on the initial exposure. Of 5 patients, 3 (60%) achieved a histologically and/or PET-CT proven CR again after re-introduction of T-VEC with a median of 3 T-VEC courses and 2 (40%) are still currently on treatment. Duration of response (time between first CR and recurrence) varied between 3.8-14.2 months. No patients developed distant metastases. Grade 1 AE’s occurred in all patients. Mostly, these consisted of fatigue, influenza-like symptoms and injection site pain. PET-CT and histological biopsies proved to be a clinically useful tool to evaluate treatment response for T-VEC monotherapy.

Conclusions

Response to re-introduction of T-VEC monotherapy in this select patient population is promising. This real world data on re-introduction of T-VEC monotherapy in stage IIIB/C-IVM1a melanoma suggests T-VEC could be a treatment option for chronic disease control in this group of patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

V. Franke: Advisory / Consultancy, Research grant / Funding (institution): Amgen. M.W.J.M. Wouters: Research grant / Funding (institution): Novartis. W. Van Houdt: Advisory / Consultancy, Research grant / Funding (institution): Amgen. A.C.J. van Akkooi: Advisory / Consultancy, Research grant / Funding (institution): Amgen; Research grant / Funding (institution): novartis; Research grant / Funding (institution): BMS-Merck; Research grant / Funding (institution): Merck-Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.